-
-
-
-
-
-
-
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
-
-
-
-
-
-
-
Daré Bioscience CEO discusses pipeline and commercial shift
-
-
-
-
-
-
-
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
-
-
-
-
-
-
-
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
-
-
-
-
-
-
-
Dare Bioscience gets FDA clearance for HPV treatment phase 2 trial
-
-
-
-
-
-
-
Dare Bioscience receives $3.6 million Gates Foundation grant payment
-
-
-
-
-
-
-
Dare Bioscience receives $4 million grant installment for drug delivery
-
1,234,323 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


